<SEC-DOCUMENT>0001157523-19-000365.txt : 20190219
<SEC-HEADER>0001157523-19-000365.hdr.sgml : 20190219
<ACCEPTANCE-DATETIME>20190219084523
ACCESSION NUMBER:		0001157523-19-000365
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190213
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190219
DATE AS OF CHANGE:		20190219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SURMODICS INC
		CENTRAL INDEX KEY:			0000924717
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				411356149
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23837
		FILM NUMBER:		19613554

	BUSINESS ADDRESS:	
		STREET 1:		9924 W 74TH ST
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		9525007000

	MAIL ADDRESS:	
		STREET 1:		9924 WEST 74TH ST
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BSI CORP
		DATE OF NAME CHANGE:	19970506
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a51941885.htm
<DESCRIPTION>SURMODICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2019 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">
      <font style="font-size: 15pt"><br style="font-size: 15pt">
      </font><font style="font-family: Times New Roman; font-size: 15pt"><b>UNITED
      STATES</b></font><font style="font-size: 15pt"><br style="font-size: 15pt"></font><font style="font-family: Times New Roman; font-size: 15pt"><b>SECURITIES
      AND EXCHANGE COMMISSION</b></font><font style="font-size: 15pt"><br style="font-size: 15pt"></font><font style="font-family: Times New Roman; font-size: 15pt"><b>Washington,
      D.C. 20549</b></font><br><br><font style="font-family: Times New Roman; font-size: 16pt"><b>FORM
      8-K</b></font><br><br><font style="font-family: Times New Roman; font-size: 12pt"><b>CURRENT
      REPORT</b></font><b><font style="font-family: Times New Roman; font-size: 12pt"><br style="font-size: 12pt; font-family: Times New Roman"></font><font style="font-family: Times New Roman; font-size: 12pt">PURSUANT
      TO SECTION 13 OR 15(d)&#160;OF THE</font><font style="font-family: Times New Roman; font-size: 12pt"><br style="font-size: 12pt; font-family: Times New Roman"></font><font style="font-family: Times New Roman; font-size: 12pt">SECURITIES
      EXCHANGE ACT OF 1934</font></b><br><br><br>
    </p>
    <div style="text-align:center">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; margin-left:auto;margin-right:auto; width: 65%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt">
            <font style="font-family: Times New Roman; font-size: 10pt"><b>February
            13, 2019</b></font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" valign="top">
          Date of report (Date of earliest event reported)
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <br>

    </p>
    <div style="text-align:center">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; margin-left:auto;margin-right:auto; width: 75%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 16pt"><b>Surmodics, Inc.</b></font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" valign="top">
          (Exact Name of Registrant as Specified in its Charter)
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <br>

    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 33%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Minnesota</b>
          </p>
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; padding-right: 0.0px; border-bottom-style: solid; white-space: nowrap; text-align: center; border-bottom-color: black; width: 32%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>0-23837</b>
          </p>
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; padding-right: 0.0px; border-bottom-style: solid; white-space: nowrap; text-align: center; border-bottom-color: black; width: 33%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>41-1356149</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center; width: 33%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (State of Incorporation)
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; text-align: center; width: 32%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (Commission File Number)
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; text-align: center; width: 33%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (I.R.S. Employer
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 33%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>9924 West 74<sup>th</sup> Street</b>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Eden Prairie, Minnesota</b>
          </p>
        </td>
        <td style="width: 34%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; padding-right: 0.0px; border-bottom-style: solid; white-space: nowrap; text-align: center; border-bottom-color: black; width: 33%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>55344</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center; width: 33%" valign="bottom">
          <font style="font-family: Times New Roman; font-size: 10pt">(Address
          of Principal Executive Offices)</font>
        </td>
        <td style="width: 34%">

        </td>
        <td style="padding-left: 0.0px; text-align: center; width: 33%" valign="bottom">
          <font style="font-family: Times New Roman; font-size: 10pt">(Zip
          Code)</font>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-align:center">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; margin-left:auto;margin-right:auto; width: 65%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; padding-right: 0.0px; border-bottom-style: solid; white-space: nowrap; text-align: center; border-bottom-color: black" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>(952) 500-7000</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" valign="top">
          (Registrant&#8217;s Telephone Number, Including Area Code)
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-indent: 30.0px; font-size: 10pt">
      <font style="font-family: Times New Roman; font-size: 10pt">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions&#160; </font>(see General Instruction A.2):
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <p style="text-align: justify">
      Indicate by check mark whether the registrant is an emerging growth
      company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
      of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
      (&#167;240.12b-2 of this chapter).
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="width: 95%">

        </td>
        <td style="width: 5%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: right; width: 95%" valign="top">
          Emerging growth company
        </td>
        <td style="padding-left: 0.0px; text-align: center; width: 5%" valign="top">
          <p style="font-size: 10pt">
            <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 95%">

        </td>
        <td style="width: 5%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 95%" valign="top">
          If an emerging growth company, indicate by check mark if the
          registrant has elected not to use the extended transition period for
          complying with any new or revised financial accounting standards
          provided pursuant to Section 13(a) of the Exchange Act.
        </td>
        <td style="padding-left: 0.0px; text-align: center; width: 5%" valign="top">
          <p style="font-size: 10pt">
            <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <br>

    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; text-align: left; width: 10%" valign="top">
          <p style="font-size: 10pt">
            <b>Item 5.02</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 90%" valign="top">
          <p style="font-size: 10pt">
            <b>Departure of Directors or Certain Officers; Election of
            Directors; Appointment of Certain Officers; Compensatory
            Arrangements of Certain Officers.</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-indent: 60.0px; text-align: justify">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;On February 13, 2019, the Board of Directors (the &#8220;<u>Board</u>&#8221;)
      of Surmodics, Inc. (the &#8220;<u>Company</u>&#8221;) appointed Timothy J.
      Arens as the Company&#8217;s Vice President, Finance, and Chief Financial
      Officer, and principal financial officer, effective immediately.&#160;&#160;Mr.
      Arens had served in this role on an interim basis since May 25,
      2018.&#160;&#160;Mr. Arens, 51, will continue to serve as the Company&#8217;s Vice
      President, Corporate Development and Strategy, a role in which he has
      served since February 2013.
    </p>
    <p style="text-indent: 60.0px; text-align: justify">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Previously, from August 2011 to February 2013, Mr. Arens has
      served as the Company&#8217;s Vice President of Finance and interim Chief
      Financial Officer.&#160;&#160;From October 2010 to August 2011, Mr. Arens served
      as the Company&#8217;s General Manager, In Vitro Diagnostics.&#160;&#160;Mr. Arens
      joined the Company in February 2007 as Director, Business Development,
      and served in finance roles of increasing responsibility, including as
      Senior Director of Financial Planning and Analysis.&#160;&#160;Mr. Arens holds a
      Bachelor of Science in Finance from the University of Wisconsin-Eau
      Claire, and a Masters of Business Administration from the Carlson School
      of Management at the University of Minnesota.There were no arrangements
      or understandings between Mr. Arens and any other persons pursuant to
      which he was selected or nominated as an officer of the Company.&#160;&#160;Mr.
      Arens does not have a family relationship with any director or executive
      officer of the Company.&#160;&#160;There are no transactions or proposed
      transactions between the Company and Mr. Arens that would require
      disclosure under Item&#160;404(a) of Regulation S-K.
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; text-align: left; width: 10%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Item 5.07</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 90%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Submission of Matters to a Vote of Security Holders.</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: justify">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Annual Meeting of Shareholders of
      the Company was held on February 13, 2019.&#160;&#160;The final voting results of
      the proposals which were described in more detail in the Company&#8217;s proxy
      statement filed with the Securities and Exchange Commission on December
      21, 2018, are set forth below.
    </p>
    <p style="text-align: justify">
      1.&#160;&#160;<u>Election of Directors</u>.&#160;&#160;Each of the individuals
      nominated by the Company&#8217;s Board of Directors to serve as Class I
      directors was duly elected by the Company&#8217;s shareholders, and the final
      results of the votes cast are as follows:
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="width: 32%">

        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 22%" valign="bottom">
          For
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 22%" valign="bottom">
          Withheld
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 22%" valign="bottom">
          Broker Non-Votes
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left; width: 32%" valign="bottom">
          Ronald B. Kalich
        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 22%" valign="bottom">
          10,244,149
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 22%" valign="bottom">
          342,117
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 22%" valign="bottom">
          1,479,445
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left; width: 32%" valign="bottom">
          Shawn T McCormick
        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 22%" valign="bottom">
          10,271,172
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 22%" valign="bottom">
          315,094
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 22%" valign="bottom">
          1,479,445
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: justify">
      2.&#160;&#160;<u>Set the Number of Directors</u>.&#160;&#160;The Company&#8217;s
      shareholders approved the proposal to set the number of directors at
      seven (7) by the following vote:
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 25%" valign="bottom">
          For
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Against
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Abstain
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Broker Non-Votes
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 25%" valign="bottom">
          10,553,070
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          2,853
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          30,343
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          1,479,445
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-indent: 60.0px; text-align: justify">

    </p>
    <p style="text-align: justify">
      3.&#160;&#160;<u>Ratification of the Appointment of Deloitte &amp; Touche LLP</u>.&#160;&#160;The
      Company&#8217;s shareholders ratified the appointment of Deloitte &amp; Touche LLP
      as the Company&#8217;s independent registered public accounting firm for
      fiscal year 2019 by the following vote:
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 25%" valign="bottom">
          For
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Against
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Abstain
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Broker Non-Votes
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 25%" valign="bottom">
          11,938,009
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          104,215
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          23,487
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          -
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: justify">
      4.&#160;&#160;<u>Advisory Vote on Executive Compensation</u>.&#160;&#160;The
      Company&#8217;s shareholders approved the compensation of the Company&#8217;s named
      executive officers, on an advisory basis, by the following vote:
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 25%" valign="bottom">
          For
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Against
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Abstain
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Broker Non-Votes
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 25%" valign="bottom">
          8,620,826
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          1,632,308
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          333,132
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          1,479,445
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: justify">
      5.&#160;&#160;<u>Surmodics, Inc. 2019 Equity Incentive Plan</u>.&#160;&#160;The
      Company&#8217;s shareholders approved the Company&#8217;s 2019 Equity Incentive Plan
      by the following vote:
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 25%" valign="bottom">
          For
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Against
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Abstain
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 24%" valign="bottom">
          Broker Non-Votes
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 25%" valign="bottom">
          9,562,543
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          1,020,857
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          2,866
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 24%" valign="bottom">
          1,479,445
        </td>
      </tr>
    </table>
    </div>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; text-align: left; width: 8%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Item 7.01</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 92%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Regulation FD Disclosure.</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-indent: 60.0px; text-align: justify">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On February 18, 2019, the Company issued a press release
      announcing Mr. Aren&#8217;s appointment. The text of the press release is
      attached as Exhibit 99.1 to this Current Report on Form&#160;8-K&#160;and is
      incorporated herein by reference.
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; text-align: left; width: 8%" valign="top">
          <p style="font-size: 10pt">
            <b>Item 9.01</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 92%" valign="top">
          <p style="font-size: 10pt">
            <b>Financial Statements and Exhibits.</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; text-align: center; width: 8%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (d)
          </p>
        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 13%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Exhibit
          </p>
        </td>
        <td style="width: 1%">
          &#160;
        </td>
        <td style="width: 78%">

        </td>
      </tr>
      <tr>
        <td style="width: 8%">

        </td>
        <td style="width: 13%">

        </td>
        <td style="width: 1%">

        </td>
        <td style="width: 78%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 8%">

        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 13%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td style="width: 1%">

        </td>
        <td style="width: 78%">

        </td>
      </tr>
      <tr>
        <td style="width: 8%">

        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: left; border-bottom-color: black; width: 13%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Number</b>
          </p>
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: left; border-bottom-color: black; width: 78%" valign="bottom">
          <b>Description</b>
        </td>
      </tr>
      <tr>
        <td style="width: 8%">

        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: left; width: 13%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            99.1
          </p>
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 78%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Press Release dated February 18, 2019.
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">SIGNATURES</font>
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt">
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.<br><br><br>
    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 47%">

        </td>
        <td style="padding-left: 15.0px; text-align: left" colspan="2" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            SURMODICS, INC.
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 47%">

        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 3%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 45%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 47%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 45%" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-bottom: 2.0px; padding-left: 0.0px; text-align: left; width: 5%" valign="top">
          Date:
        </td>
        <td style="padding-bottom: 2.0px; padding-left: 0.0px; text-align: left; width: 47%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            February 18, 2019
          </p>
        </td>
        <td style="padding-left: 10.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: left; border-bottom-color: black; width: 3%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: left; border-bottom-color: black; width: 45%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/&#160;&#160;&#160;&#160;&#160;Bryan K. Phillips
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 47%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 45%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Bryan K. Phillips
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 47%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 45%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Sr. Vice President, General Counsel and Secretary
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      EXHIBIT INDEX
    </p>
    <p>

    </p>
<div style="text-align:left">
    <table style="font-family: Times New Roman; margin-bottom: 10.0px; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; text-align: center; width: 8%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 1%" valign="top">
          &#160;
        </td>
        <td style="width: 91%">

        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: center; border-bottom-color: black; width: 8%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Number</b>
          </p>
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; border-bottom-width: 1.0pt; border-bottom-style: solid; text-align: left; border-bottom-color: black; width: 91%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; text-align: center; width: 8%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <a href="a51941885ex99_1.htm">99.1</a>
          </p>
        </td>
        <td style="width: 1%">

        </td>
        <td style="padding-left: 0.0px; text-align: left; width: 91%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <a href="a51941885ex99_1.htm">Press Release dated February 18,
            2019.</a>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51941885ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2019 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Surmodics
      Announces Appointment of Timothy J. Arens as Chief Financial Officer</b></font>
    </p>
    <p>
      EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--February 18, 2019--Surmodics,
      Inc.&#160;(NASDAQ: SRDX), a leading provider of medical device and in vitro
      diagnostic technologies to the healthcare industry, today announced the
      appointment of Timothy J. Arens, Vice President of Corporate Development
      and Strategy,&#160;as the company&#8217;s new Chief Financial Officer (CFO),
      effective immediately.
    </p>
    <p>
      Arens was named interim CFO in May 2018 following the departure of
      Andrew LaFrence. Arens&#8217; corporate development and strategy
      responsibilities will be absorbed into his CFO role.
    </p>
    <p>
      &#8220;Tim has been an impressive partner to me and an invaluable contributor
      to our management team and Surmodics&#8217; success during the past eight
      years. I am personally delighted that he has been formally appointed to
      the role,&#8221; said Gary Maharaj, President and Chief Executive Officer
      of&#160;Surmodics. &#8220;Tim's excellent financial, operational and strategic
      skills and strong leadership are ideally suited to his new role as we
      continue to drive our strategic initiatives and financial goals of
      consistent and profitable long-term growth.&quot;
    </p>
    <p>
      Arens has served in his current role since February 2013. He joined
      Surmodics in February 2007 as Director, Business Development, was named
      Senior Director and General Manager of the in vitro diagnostics business
      unit in October 2010 and served as Vice President of Finance and interim
      CFO from August 2011 to February 2013.
    </p>
    <p>
      &#8220;I am excited to work with a group of dedicated and talented colleagues
      to accelerate our strategic transformation while continuing to deliver
      on our operating commitments,&#8221; said Arens. &#8220;Surmodics is well-positioned
      to execute on our strategic initiatives including the development of
      highly innovative products that benefit patients. I am looking forward
      to being part of that journey.&#8221;
    </p>
    <p>
      <b>About&#160;Surmodics, Inc.</b>
    </p>
    <p>
      Surmodics&#160;is the global leader in surface modification technologies for
      intravascular medical devices and a leading provider of chemical
      components for in vitro diagnostic immunoassay tests and
      microarrays.&#160;Surmodics&#160;is pursuing highly differentiated whole-product
      solutions that are designed to address unmet clinical needs for its
      medical device customers and engineered to the most demanding
      requirements. This key growth strategy leverages the combination of the
      Company&#8217;s expertise in proprietary surface technologies, along with
      enhanced device design, development and manufacturing capabilities. The
      Company mission remains to improve the detection and treatment of
      disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more
      information, visit <u>www.surmodics.com</u>. The content of Surmodics&#8217;
      website is not part of this press release or part of any filings that
      the company makes with the SEC.
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-right: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Safe Harbor for Forward-Looking Statements</b>
    </p>
    <p>
      This press release contains forward-looking statements. Statements that
      are not historical or current facts are forward-looking statements.
      Forward-looking statements involve inherent risks and uncertainties, and
      important factors could cause actual results to differ materially from
      those anticipated, including the factors identified under &#8220;Risk Factors&#8221;
      in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year
      ended&#160;September 30, 2018, and updated in our subsequent reports filed
      with the&#160;SEC. These reports are available in the Investors section of
      our website at&#160;<u>www.surmodics.com</u>&#160;and at the&#160;SEC&#160;website at&#160;<u>www.sec.gov</u>.
      Forward-looking statements speak only as of the date they are made, and
      we undertake no obligation to update them in light of new information or
      future events.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>Surmodics, Inc.<br>Tim Arens, 952-500-7000<br><u>ir@surmodics.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
